Head-To-Head Analysis: Candel Therapeutics (NASDAQ:CADL) vs. Outlook Therapeutics (NASDAQ:OTLK)

Outlook Therapeutics (NASDAQ:OTLK) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Volatility and Risk

Outlook Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -1.2, suggesting that its share price is 220% less volatile than the S&P 500.

Profitability

This table compares Outlook Therapeutics and Candel Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Outlook Therapeutics	N/A	N/A	-160.88%
Candel Therapeutics	N/A	-629.29%	-173.39%

Earnings and Valuation

This table compares Outlook Therapeutics and Candel Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Outlook Therapeutics	N/A	N/A	-$58.98 million	($8.94)	-0.26
Candel Therapeutics	$120,000.00	2,259.79	-$37.94 million	($1.73)	-4.83

Candel Therapeutics has higher revenue and earnings than Outlook Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Outlook Therapeutics and Candel Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Outlook Therapeutics	0	1	6	0	2.86
Candel Therapeutics	0	0	1	0	3.00

Outlook Therapeutics currently has a consensus price target of $32.73, indicating a potential upside of 1,323.19%. Candel Therapeutics has a consensus price target of $19.00, indicating a potential upside of 127.54%. Given Outlook Therapeutics’ higher probable upside, research analysts clearly believe Outlook Therapeutics is more favorable than Candel Therapeutics.

Insider & Institutional Ownership

11.2% of Outlook Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 3.4% of Outlook Therapeutics shares are owned by insiders. Comparatively, 41.6% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

About Outlook Therapeutics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

About Candel Therapeutics

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.